On May 2021, the FDA granted accelerated approval to infigratinib for previously treated locally advanced CCA or for patients with metastatic CCA with FGFR2 fusions or FGFR2 rearrangements [19]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.